The Center for Design and Synthesis of Molecularly Targeted Radiopharmaceuticals (CERAD) aims to develop a modern infrastructure dedicated to research into new diagnostic/therapy radiopharmaceuticals based on biologically active ligands at the cellular and molecular levels. By combining radioactive isotopes with disease molecular markers, it may be possible to diagnose serious diseases and apply appropriate treatments earlier than before. 

The CERAD laboratories will be equipped with a cyclotron capable of accelerating protons and alpha particles up to an energy of 30 MeV and deuterons up to 15 MeV. This accelerator will enable the production of new radioactive isotopes, such as 89Zr, 211At, or 67Cu, and facilitate the creation of innovative radiopharmaceuticals for diagnostics and therapy. Upon project completion in 2024, NCBJ will be a unique center capable of producing radioisotopes both in the reactor and with the cyclotron.

CERAD